Hedgehog (HH) signalling governs embryogenesis and adult tissue homeostasis in mammals and other multicellular organisms 1-3 . Whereas deficient HH signalling leads to birth defects, unrestrained HH signalling is implicated in human cancers 2,4-6 . N-terminally palmitoylated HH releases the repression of Patched to the oncoprotein smoothened (SMO); however, the mechanism by which HH recognizes Patched is unclear. Here we report cryoelectron microscopy structures of human patched 1 (PTCH1) alone and in complex with the N-terminal domain of 'native' sonic hedgehog (native SHH-N has both a C-terminal cholesterol and an N-terminal fatty-acid modification), at resolutions of 3.5 Å and 3.8 Å, respectively. The structure of PTCH1 has internal two-fold pseudosymmetry in the transmembrane core, which features a sterol-sensing domain and two homologous extracellular domains, resembling the architecture of Niemann-Pick C1 (NPC1) protein The HH precursor undergoes autocatalytic processing in the endoplasmic reticulum to release an amino-terminal signalling domain (HH-N) with cholesterol covalently coupled to its carboxyl terminus. Hedgehog acyltransferase then adds palmitate to the α-amino group of the N-terminal-specific cysteine to yield the mature, doubly lipidated signalling molecule 9, 10 . N-terminal palmitoylation is indispensable for HH signalling: (1) fatty-acylated SHH-N is far more active than unacylated SHH-N, as determined from differentiation assays and HH signalling assays 11, 12 ; (2) blocking HH-N palmitoylation (by mutation of its palmitoylation site) was shown to affect embryonic development in Drosophila and in mice 10, 13 ; and (3) inhibitors of hedgehog acyltransferase that prevent the palmitoylation of SHH block HH signalling 14 . Human patched 1 (PTCH1), the primary receptor for HH-N ligands, consists of 1,447 amino acids, including 12 transmembrane helices and three approximately 30-kD soluble domains, namely two extracellular domains (ECD-I and ECD-II) that bind HH-N and one cytoplasmic carboxyl-terminal domain (CTD) (Fig. 1a, Extended  Data Fig. 1 ). In addition, transmembrane helices 2-6 (TM2-TM6) of Patched are predicted to form a sterol-sensing domain (SSD), which, in other proteins such as NPC1 and HMG-CoA reductase, is involved in cholesterol metabolism and signalling . In support of this model, Patched has a similar transmembrane topology to NPC1 and prokaryotic resistance-nodulation-cell division (RND) transporters, which transport ligands across membranes 7, 19 . Two major gaps remain in our knowledge of the HH pathway: (1) the molecular details of how HH recognizes and binds Patched; and (2) the mechanism of SMO activation after HH binds Patched. More importantly, Patched is a tumour suppressor involved in basal cell carcinoma,
; (2) blocking HH-N palmitoylation (by mutation of its palmitoylation site) was shown to affect embryonic development in Drosophila and in mice 10, 13 ; and (3) inhibitors of hedgehog acyltransferase that prevent the palmitoylation of SHH block HH signalling 14 . Human patched 1 (PTCH1), the primary receptor for HH-N ligands, consists of 1,447 amino acids, including 12 transmembrane helices and three approximately 30-kD soluble domains, namely two extracellular domains (ECD-I and ECD-II) that bind HH-N and one cytoplasmic carboxyl-terminal domain (CTD) (Fig. 1a , Extended Data Fig. 1 ). In addition, transmembrane helices 2-6 (TM2-TM6) of Patched are predicted to form a sterol-sensing domain (SSD), which, in other proteins such as NPC1 and HMG-CoA reductase, is involved in cholesterol metabolism and signalling 15 . Unliganded Patched inhibits HH signalling and this repression is released when HH binds to Patched 16 . Specifically, after HH binding, Patched releases its inhibition of SMO, a polytopic membrane receptor that activates the Gli transcription factors to upregulate HH target genes 2 . How Patched inhibits SMO is unknown, but there are studies that show that Patched may act indirectly by releasing a small molecule to regulate SMO 17, 18 . In support of this model, Patched has a similar transmembrane topology to NPC1 and prokaryotic resistance-nodulation-cell division (RND) transporters, which transport ligands across membranes 7, 19 . Two major gaps remain in our knowledge of the HH pathway: (1) the molecular details of how HH recognizes and binds Patched; and (2) the mechanism of SMO activation after HH binds Patched. More importantly, Patched is a tumour suppressor involved in basal cell carcinoma,
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TM8-TM12 TM1 TM7 Letter reSeArCH medulloblastoma and primitive neuroectodermal tumours 5 , and mutations of SHH and PTCH1 can also cause developmental defects 3 . SMO is a target of antitumour agents 20 . Because this pathway is associated with human diseases, structural knowledge of Patched and the Patched-HH complex is crucial not only for elucidating the mechanism of signal transduction, but also for understanding the pathology of mutants and for the development of potential therapeutics for human diseases.
The full-length human PTCH1, expressed with a C-terminal Flag tag in human embryonic kidney (HEK)-293S cells, is eluted in the void volume during gel filtration (Extended Data Fig. 2a) . To make the protein amenable to structural studies, we truncated the cytoplasmic loop between TM6 and TM7 and the CTD of PTCH1. A recent study on PTCH1 revealed that simultaneous deletion of both its TM6-TM7 internal loop and its cytoplasmic domain did not affect PTCH1-dependent repression of SMO activity in PTCH1-deficient MEFs or normal localization in cilia 21 . This suggests a structural or mechanistic interaction between the TM6-TM7 internal loop and the CTD, because deletion of the CTD in combination with this loop restores normal activity. This PTCH1 variant (PTCH1*) has better solubility (Extended Data Fig. 2b) . To test the function of PTCH1*, either PTCH1* or full-length PTCH1 was transfected to PTCH1-deficient MEFs. HH reporter assays reveal that, similar to wild-type PTCH1, PTCH1* can repress HH signalling. They also reveal that treatment with conditioned medium containing palmitoylated SHH-N without the cholesterol modification, but not the C24S palmitoylation-site SHH-N mutant, can release this repression (Fig. 1b) .
We assembled the PTCH1*-SHH-N complex using unmodified SHH-N with an N-terminal His tag purified from Escherichia coli, or SHH-N with a C-terminal cholesterol and an N-terminal fatty-acid modification purified from HEK-293 cells (termed 'native' SHH-N hereafter) (Fig. 1c) . The native SHH-N, but not unmodified SHH-N, formed a stable complex with PTCH1*, with SHH-N being detected at a 1:1 ratio (Fig. 1c) . We also measured HH signalling activity in cells by adding either conditioned media or purified SHH-N proteins to SHH Light II cells that carry a Gli reporter plasmid. The results show that palmitoylated SHH-N, but not the C24S SHH-N mutant or NHis-tagged SHH-N, can stimulate HH signalling considerably (Fig. 1d) . This suggests that PTCH1* is able to bind the native SHH-N, allowing us to make a physiological complex with purified PTCH1* in vitro (Extended Data Fig. 2c) .
We determined the structure of PTCH1* to 3.5 Å resolution (Fig. 2a , Extended Data Figs. 3, 4, Extended Data Table 1 ). PTCH1*, a monomer in solution, measures 110 Å × 60 Å × 40 Å (Fig. 2a) . The structure exhibits pseudosymmetry across the 12 transmembrane helices and features two homologous extracellular domains (Fig. 2a) . The transmembrane domain of Patched has a similar topology to NPC1 and to prokaryotic RND transporters 7, 19 , one of which is AcrB (Fig. 2b, c) . Previous studies have suggested that PTCH1 could form oligomers mediated by its CTD 22 ; because this part of the molecule has been removed in our construct, we focus our discussion on monomeric PTCH1*.
Previous crosslinking studies have suggested that the SSD of NPC1 may bind a small ligand 23 . We have shown previously that a cavity in the SSD of NPC1 is large enough to accommodate a cholesterol molecule 7 . A corresponding pocket is observed in the SSD of PTCH1* (Fig. 2d, Extended Data Fig. 5 ). This hydrophobic pocket opens to the extracellular space and plasma membrane and measures roughly 20 Å × 10 Å × 10 Å (Fig. 2d) . Remarkably, we observed a rod-shaped density in this pocket (Fig. 2d) , which is distinct from detergent micelles and other noise on the basis of its local resolution. We speculate that the density might derive from an endogenous sterol derivative or another lipid. Structural comparison of PTCH1* and NPC1 reveals that the transmembrane helices of the N-terminal half of PTCH1* converge more closely than those in NPC1, potentially owing to an interaction with this unidentified ligand (Fig. 2d) .
ECD-I and ECD-II overlap with each other with a root-mean-square deviation (r.m.s.d.) of 3.8 Å (Cα atoms) and resemble the middle and Letter reSeArCH C-terminal lumenal domains of NPC1 24 . Each ECD consists of two subdomains: subdomain 1 ranges from the cell membrane to the middle of each ECD, with three β strands and two α helices providing the main interface between the two extracellular domains; each subdomain 2 ranges from the middle to the top of each ECD (Fig. 2e) . There are five residues of the swapped ECD-I α1 helix that interact with 
Letter reSeArCH six residues in ECD-II in addition to several hydrophobic interactions. By contrast, ECD-II α1 (labelled as α1*) forms only one hydrophilic bond with T426 in α4 of ECD-I (Fig. 2f) . Moreover, ECD-I contains 70 amino acids more than does ECD-II, and subdomain 2 of ECD-I contains more loops than does subdomain 2 of ECD-II (Extended Data Fig. 1 ). Together, these features confer a flexible character to ECD-I for ligand binding. The structure of the PTCH1*-SHH-N complex was determined to 3.8 Å resolution (Fig. 3a, Extended Data Figs. 6, 7 , Extended Data Table 1 ). The C terminus of SHH-N (residues 187-197), which was also invisible in the SHH-N crystal structure (Protein Data Bank (PDB) code 3M1N), could not be resolved. This result supports our cell biological assays that cholesterol modification of HH-N is not necessary to stimulate the HH signal (Fig. 1b, d ). In addition to the molecule observed in the SSD, there is another endogenous density close to TM12 (Fig. 3a) . This helix is slightly more tilted than in the apostructure, potentially using the guanidine group of Arg1150 to bind the polar head of this putative lipid (Fig. 3b) . There is no substantial conformational change between the transmembrane regions of PTCH1* alone and the PTCH1*-SHH-N complex (Fig. 3b) . This suggests that SHH-N binding may not abolish SSD-mediated substrate binding of PTCH1.
Native SHH-N engages two binding sites on the ECD-I of PTCH1* (Fig. 3a) . The primary interface involves the N-terminal peptide of SHH-N (residues 24-38), with fatty-acid modification that fits into the space between subdomains 1 of ECD-I and ECD-II (Fig. 3c ). This binding site includes a strong stretch of density that extends beyond the N-terminal Cys24 and that is contiguous with the protein. Mass spectrometry has identified this extension on the SHH-N that we used as primarily palmitoylation and to a smaller degree lauryolation and myristoylation, consistent with previous observations 25 . On the basis of this result and the shape of the density, we assign the N-terminal density as a palmitoyl moiety (Fig. 3c, Extended Data Fig. 7e) . Compared with the apo-PTCH1* structure, the α3 and α3′ helices and their connecting loop in ECD-I are shifted towards the membrane side, providing more space for this insertion (Fig. 3d) . The loop that connects α1 and β1 of ECD-I (residues 148-153) undergoes a conformational change that allows palmitate to expand the space between α1 of ECD-I and α4 of ECD-II (Fig. 3d) . Hydrophobic residues from extracellular domains form extensive van der Waals interactions with this modification (Fig. 3c) . The secondary binding site involves α helices α1 and α2 of SHH-N, whereas PTCH1* engages its ECD-I (Fig. 3e) . A recent study showed that a short palmitoylated N-terminal fragment (residues 24-45) of SHH-N could partially activate HH signalling by binding PTCH1 11 . Our work shows that native SHH-N indeed forms a more stable complex with PTCH1* than does unpalmitoylated SHH-N (Fig. 1c) and our structure confirms the interaction between the SHH-N palmitate and PTCH1* (Fig. 3c) .
The interface that we observed between the native SHH-N and PTCH1* was inconsistent with a previously reported interface of SHH-N and PTCH1* that includes the zinc-binding site (Fig. 3a) , which is also able to accommodate calcium and putatively binds to PTCH1 21, 26, 27 . To resolve this contradiction, we purified N-His-tagged SHH-N without the palmitate from E. coli as previously reported 26 ; however, our cell-based HH reporter assays show that the N-His-tagged SHH-N lost almost all HH signalling activity (Fig. 1d) . Compared with native SHH-N, removing the palmitate modification of SHH-N or deleting the N terminus (residues 24-36) weakened SHH-N binding to PTCH1* (Fig. 4a) . Interestingly, binding between N-His-tagged SHH-N and PTCH1* could be enhanced by Ca
2+
; however, the binding between native SHH-N and PTCH1* was not affected by Ca 2+ (Fig. 4b) .
We performed further SHH-N competition assays with PTCH1* and 5E1, a monoclonal anti-SHH-N antibody of nanomolar binding affinity that is used to block HH signalling by binding PTCH1 8 ( Fig. 4c) . Our structural analysis predicts that 5E1 should not interfere with the palmitate-dominated interface to PTCH1*. To validate this point, we performed a pull-down assay in the presence of 5E1 to determine whether it competes with PTCH1* to bind native SHH-N or N-terminally tagged SHH-N. SHH-N was mixed with 5E1 before being incubated with PTCH1* immobilized on a Flag M2 resin. A PTCH1*-SHH-N-5E1 trimeric complex could be eluted, which suggests that binding of 5E1 to native SHH-N does not block its access to the observed PTCH1* interface. By contrast, 5E1 successfully competed with N-His-tagged SHH-N to bind PTCH1* with and without Ca 2+ (Fig. 4d) . To exclude the possibility that detergent may have had an undesirable influence in our system, we also reconstituted PTCH1* with amphipols, which stabilize membrane proteins in solution, and repeated the competition assays (Extended Data Fig. 8a) . The results show that, as in the presence of detergents, the PTCH1*-SHH-N-5E1 trimeric complex could be detected in a detergent-free environment (Extended Data Fig. 8b) . Therefore, our data suggest that the palmitoylated N terminus of SHH-N is an integral part of the native SHH-N-PTCH1* interface and that when its palmitoylated N terminus is absent the 5E1-binding interface (including R153 and the Ca 2+ binding site) may dominate in PTCH1* binding (Fig. 4c) .
To verify the secondary interface further, we used unmodified SHH-N without any lipidation or tag at the N terminus and further blocked the previously reported interface on SHH-N with 5E1. In our binding assays, unmodified SHH-N still bound PTCH1* by the secondary interface in the presence of 5E1, which blocks the previously reported interface (Fig. 4e) . We then introduced mutations on helix α1 of SHH-N(I111E/N115K), which abolished binding to PTCH1* Letter reSeArCH (Fig. 4e) . The HH reporter assays show that the SHH-N(I111E/N115K) mutant-conditioned medium lost more than 70% of activity compared with wild-type SHH-N (Fig. 1d) . These data may explain why mutation of I111 or N115 leads to HPE-3, possibly by altering how PTCH1 recognizes SHH-N. We also introduced alanine mutations on the ECD-I(E221A/Y222A/L223A/Y224A) of PTCH1* (shown as ' AAAA' and L254A/W256A in Fig. 3e in red) . The binding assays show that these two mutants have weaker binding to the SHH-N-5E1 complex, further supporting our structural observations (Fig. 4f) . The HH reporter assays also show that in Ptch1 −/− MEFs the full-length PTCH1 with ' AAAA' mutations can repress HH signalling but cannot recognize SHH-N to release the inhibition (Fig. 4g) .
Here, we have reported two structures and related structure-guided experiments that together reveal that PTCH1* recognizes native SHH-N by two distinct binding sites. The PTCH1*-SHH-N interface that we describe here has important implications of how SHH-N recognizes and interacts with other proteins in various signalling pathways, including Ihog (interference hedgehog), Cdo (cell-adhesionmolecule-related, downregulated by oncogenes), Boc (brother of Cdo) and Hhip (hedgehog-interacting protein) 8 . These co-receptors function in the recognition and localization of HH in various cell types 28, 29 . Previous studies have suggested that HH-N could form a complex with Patched and its co-receptor 28, 30 . The PTCH1*-SHH-N complex structure that we determined indeed allows for SHH-N to interact with an additional co-receptor to form multivalent complexes (Fig. 5a, b) . This architecture is corroborated by our finding that the interaction of SHH-N with the antibody 5E1, which binds the same area of PTCH1 as does the SHH-N co-receptors, does not interfere with the formation of the PTCH1*-SHH-N complex (Fig. 4d) . We propose a PTCH1-SHH-N working model: SHH-N initially recognizes PTCH1 through its palmitoylated N terminus; subsequently, SHH-N co-receptors or another PTCH1 binds SHH-N at a distinct interface to further regulate HH signalling (Fig. 5c) . This model could provide a possible mechanism for how HH-N co-receptors and PTCH1 orchestrate HH signalling. The other aspect of Patched signalling-the mechanism for inhibition of SMO-remains poorly understood. Further investigations are required into how the HH-N ligand affects the putative transport activity of Patched.
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MEthodS
Protein expression and purification. The constructs of human patched 1 were cloned into pEG BacMam with a C-terminal Flag tag. The protein was expressed using baculovirus-mediated transduction of mammalian HEK-293S GnTI − cells (ATCC). The cell lines tested negative for mycoplasma contamination. At 48 h post-infection at 37 °C, cells were disrupted by sonication in buffer A (20 mM Hepes pH 7.5, 150 mM NaCl) with 1 mM phenylmethanesulfonyl fluoride (PMSF), 10 μg ml −1 leupeptin. After low-speed centrifugation, the resulting supernatant was incubated in buffer A with 1% (w/v) n-dodecyl-β-d-maltoside (DDM, Anatrace) for 1 h at 4 °C. The lysate was centrifuged again and the supernatant was loaded onto an anti-Flag M2 affinity column (Sigma). After washing twice, the protein was eluted in buffer A with 0.1 mg ml −1 Flag peptide, 0.02% DDM, and concentrated. The concentrated protein was purified by Superdex-200 size-exclusion chromatography (GE Healthcare) in buffer B (20 mM Hepes pH 7.5, 150 mM NaCl and 0.06% (w/v) Digitonin (Sigma)). The peak fractions were collected and concentrated to 5-7 mg ml −1 for grid preparation. Mass spectrometry and antiFlag-tag western blotting confirmed the identity of the protein. To assemble the PTCH1*-SHH-N complex, native SHH-N (purchased from R&D system, catalogue number 8908-SH/CF) was mixed with purified PTCH1* at a 1:1 molar ratio and purified by Superdex-200 size-exclusion chromatography (GE Healthcare) in buffer B. The peak fractions were collected and concentrated to 5-7 mg ml −1 for grid preparation.
For preparation of detergent-free protein, PTCH1* was purified as above and then mixed with Amphipol A8-35 (Anatrace) at a 1:3 mass ratio for 4 h. This mixture was incubated with Bio-Beads (Bio-Rad) overnight before further purification by gel filtration with buffer A. The mutated and truncated DNA constructs were generated using two-step PCR or Gibson assembly (NEB).
Three constructs were cloned into the pET21b vector: (1) human SHH-N (residues with N-terminal His tag; (2) human SHH-N (residues 25-197) with C-terminal His tag; and (3) human SHH-N (residues 37-197) with C-terminal His tag. All of the constructs and SHH-N variants were then transformed into E. coli BL21 (DE3) for expression. The transformed bacteria were grown in LB medium supplemented with ampicillin at 37 °C and induced by 0.2 mM isopropyl β-d-thiogalactopyranoside (IPTG) overnight at 25 °C. The cells were harvested and lysed by sonication in buffer C (20 mM Hepes pH 7.5, 500 mM NaCl) supplemented with 1 mM PMSF. The lysate was centrifuged at 18,000 r.p.m. for 30 min and the supernatant was loaded onto a Ni 2+ -NTA affinity column (Qiagen). After washing three times with 20 mM, 40 mM and 80 mM imidazole in buffer C, the protein was eluted in buffer C plus 250 mM imidazole and further purified by gel filtration using Superdex-200 size-exclusion chromatography (GE Healthcare) in buffer C. Peak fractions were collected for pull-down assay. Electron microscopy sample preparation and imaging. A freshly purified protein sample was added to Quantifoil R1.2/1.3 400 mesh Au holey carbon grids (Quantifoil), blotted using a Vitrobot Mark IV (FEI), and frozen in liquid ethane. The grids were imaged in a 300-keV Titan Krios (FEI) with a Gatan K2 Summit direct electron detector (Gatan). Data were collected at 1 Å per pixel with a dose rate of 8 electrons per physical pixel per second. Images were recorded for 10-s exposure in 50 subframes to give a total dose of 80 electrons per Å 2 . Imaging processing and 3D reconstruction. Dark subtracted images were first normalized by gain reference that resulted in a pixel size of 1 Å per pixel. Drift correction was performed using the program Unblur 31 . The contrast transfer function (CTF) was estimated using CTFFIND4 32 . To generate PTCH1* templates for automatic picking, around 2,000 particles were manually picked and classified by 2D classification in RELION 33 . After auto-picking in RELION, the low-quality images and false-positive particles were removed manually. About 790,000 particles were extracted for subsequent 2D and 3D classification. 3D classification was carried out in RELION to generate the initial model of PTCH1 * , using the cryo-EM structure of human NPC1 (Electron Microscopy Data Bank, EMD-6640) low-pass-filtered to 60 Å as the initial model. The PTCH1* model of best class after 3D classification was used as the initial model for the final 3D classification in RELION. The best class, containing around 168,000 particles, provided a 7.7 Å map after 3D autorefinement in RELION. Motion correction of all particles was performed using the program alignparts_lmbfgs 34 . As in a previously published approach 35 , refinement was performed in FREALIGN 36 using this best class as the initial model. The global search was performed once followed by 10-20 rounds of local search without mask. The best class without mask refinement was selected to generate the mask using relion_mask_create with 6 Å extensions excluding the micelle. This mask was then used to perform another global search followed by 10-20 rounds of local search with a cosine edge width of 6 Å and a BSC value of 10 to exclude bad particles. The final map is estimated to be 3.5 Å using the 0.143 cut-off criteria.
To generate templates of the PTCH1*-SHH-N complex for automatic picking, around 5,000 particles were picked manually and classified by 2D classification in RELION 33 . After auto-picking in RELION, the low-quality images and falsepositive particles were removed manually. About 661,000 particles were extracted for subsequent 2D and 3D classification. 3D classification was carried out in RELION using the cryo-EM structure of PTCH1* low-pass-filtered to 60 Å as the initial model. The complex model of best class after 3D classification was used as the initial model for the final 3D classification in RELION. The best class, containing 195,000 particles, provided a 7.1 Å map after 3D auto-refinement in RELION. After motion correction of individual particles, the final refinement was performed in FREALIGN 36 using this best class as the initial model. The global search was performed once followed by 10-20 rounds of local search without mask. The best class without mask refinement was selected to generate the mask using relion_mask_create with 6 Å extensions excluding the micelle. This mask was then used for performing another global search followed by 10-20 rounds of local search with a cosine edge width of 6 Å. The final map is estimated to be 3.8 Å using the 0.143 cut-off criteria. Model construction. To obtain better side-chain densities for model building, we sharpened the map of PTCH1* using bfactor.exe (author, Nikolaus Grigorieff) with a resolution limit of 3.5 Å and a B-factor value of −100 Å 2 . The entire model was built de novo in Coot 37 . The crystal structure of human NPC1 (residues 334-1,278, PDB code 5U74) and the glycosylation sites of the PTCH1* extracellular domains were used to check the registers of our model. The de novo models of ideal helices were first put into the transmembrane region. Using the bulky size of some large side chains in the cryo-EM map, we assigned a sequence to the initial model. The model was refined using phenix.real_space_refine with real-space restraints, including secondary-structure, stereochemical, Ramachandran and rotamer restrains, to accommodate the bending of helices, maintain the stereochemistry of the helical structure and best fit the model and cryo-EM map. Finally, the two extracellular domains were added to the model gradually, at the same time as the sequence assignment Model refinement and validation. The models of PTCH1* and its complex with SHH-N were refined in real space using PHENIX 38 and in reciprocal space using Refmac with secondary-structure restraints and stereochemical restraints 39, 40 . Structure factors were calculated from a half-map (working) using the program SFall 41 . Fourier shell correlations (FSCs) were calculated between the two half maps, the model against the working map, the other (free) half map and full (sum) map 42 . Local resolutions were estimated using Blocres 43 . MolProbity 44 was used to validate the geometries of the model. Structure figures were generated using PyMOL (http://www.pymol.org) and Chimera 45 . Pull-down assay. The unmodified human SHH-N proteins were expressed and purified from E. coli as described above. The HEK-293-derived native human SHH-N protein was purchased from R&D Systems (catalogue number 8908-SH/CF; see the LC/ESI-mass spectrometry analysis of this protein at http://bit.ly/2Ao-hYCG). For the pull-down assay, purified PTCH1* protein was immobilized to 20 μl anti-Flag M2 resin, which was further incubated with unmodified or native SHH-N for 1 h at 4 °C in 150 μl buffer B. Then the resin was spun down and washed three times with buffer B. The protein complex was eluted with 20 μl buffer B supplemented with 0.3 mg ml −1 Flag peptide. 15 μl of the elution was loaded on SDS-PAGE for detection. To see whether 5E1 competes with PTCH1* when binding SHH-N, 5E1 (from B. Chen and J. Kim, UT Southwestern) was added to SHH-N before incubating with the PTCH1*-immobilized anti-Flag M2 resin. For the pull down of the SHH-N-5E1 complex, the SHH-N (E. coli expressed with C-terminal His tag) was incubated with 5E1 at 1:1 molar ratio, and then the pull-down assays were performed as above. The SHH-N protein and PTCH1* were detected by anti-SHH antibody (sc-365112, Santa Cruz Biotechnology) and anti-Flag antibody (M185, MBL Life Science). For the detergent-free assay, buffer B was replaced by buffer A. Each assay was reproduced at least three times. HH reporter assays. Human SHH-N (24-197) was constructed into pcDNA3.1 vector with the signal sequence of human calreticulin at the N terminus as described previously The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
No statistical method was used to determine sample size.
Data exclusions No data was excluded.
Replication
Each experiment was reproduced at least four times on separate occasions. Experimental findings were reliably reproduced.
Randomization The study did not involve animals or human research participants thus samples were not randomized for the experiments.
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The study did not involve animals or human research participants thus thus no blinding was used.
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